Rapid Ebola Virus Detection Assay Evaluated
By LabMedica International staff writers Posted on 17 Nov 2015 |

Image: The Diagnostics-in-a-Suitcase used to screen for Ebolavirus disease (Photo courtesy of Institut Pasteur, Dakar).
Ebolavirus (EBOV) infection is mainly diagnosed by various in-house and commercial real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays used in up to 38 laboratories implemented at or close to Ebola treatment centers (ETC) in West Africa.
Transmission of Ebolavirus disease (EVD) occurs almost exclusively from human to human by direct contact with body fluids of symptomatic cases. Consequently, the control strategy for EVD epidemics relies on early identification of EBOV-infected patients and corpses for, respectively, isolation and safe burials.
An international team of scientists led by those at the Institut Pasteur de Dakar (Dakar, Senegal) evaluated a new nucleic acid extraction kit on sera and swabs in combination with an improved diagnostic reverse transcription recombinase polymerase amplification assay for the detection of Ebolavirus (EBOV-RT-RPA) that was compared in parallel to other methods. Serum samples from acute cases and cheek and tongue swabs from deceased were collected. In addition, following an upsurge of EVD cases connected to funeral rites, oral swabs from all deceased were tested at the morgue.
The extraction kit tested was the SpeedXtract Nucleic Acid Kit (SE), (Qiagen; Hilden, Germany). The W-PCR was performed on the SmartCycler (Cepheid; Sunnyvale, CA, USA) using the RNA Master Hybridisation Probes kit (Roche; Manheim, Germany). A mobile laboratory was used which consisted of a glovebox, a Diagnostics-in-a-Suitcase (DiaS), and a solar panel and power pack set. The RT-RPA was performed using a custom-made EBOV-specific exo RT kit with pellets containing optimized enzyme concentrations.
The EBOV-RT-RPA was evaluated in comparison to two real-time PCR assays. The prevalence of EBOV in the swabs tested was 12.9%. The day of death after onset of disease peaked at day 6 (range: 2 to14 days) in the group of 67 swab-positive deceased for whom disease symptoms were recorded. Of 928 post-mortem swabs, 120 tested positive, and the combined SE and EBOV-RT-RPA yielded a sensitivity and specificity of 100% in reference to one real-time RT-PCR assay. Another widely used real-time RT-PCR was much less sensitive than expected. Results were provided very fast within 30 to 60 minutes, and the field deployment of the mobile laboratory helped improve burial management and community engagement.
Related Links:
Institut Pasteur de Dakar
Qiagen
Cepheid
Transmission of Ebolavirus disease (EVD) occurs almost exclusively from human to human by direct contact with body fluids of symptomatic cases. Consequently, the control strategy for EVD epidemics relies on early identification of EBOV-infected patients and corpses for, respectively, isolation and safe burials.
An international team of scientists led by those at the Institut Pasteur de Dakar (Dakar, Senegal) evaluated a new nucleic acid extraction kit on sera and swabs in combination with an improved diagnostic reverse transcription recombinase polymerase amplification assay for the detection of Ebolavirus (EBOV-RT-RPA) that was compared in parallel to other methods. Serum samples from acute cases and cheek and tongue swabs from deceased were collected. In addition, following an upsurge of EVD cases connected to funeral rites, oral swabs from all deceased were tested at the morgue.
The extraction kit tested was the SpeedXtract Nucleic Acid Kit (SE), (Qiagen; Hilden, Germany). The W-PCR was performed on the SmartCycler (Cepheid; Sunnyvale, CA, USA) using the RNA Master Hybridisation Probes kit (Roche; Manheim, Germany). A mobile laboratory was used which consisted of a glovebox, a Diagnostics-in-a-Suitcase (DiaS), and a solar panel and power pack set. The RT-RPA was performed using a custom-made EBOV-specific exo RT kit with pellets containing optimized enzyme concentrations.
The EBOV-RT-RPA was evaluated in comparison to two real-time PCR assays. The prevalence of EBOV in the swabs tested was 12.9%. The day of death after onset of disease peaked at day 6 (range: 2 to14 days) in the group of 67 swab-positive deceased for whom disease symptoms were recorded. Of 928 post-mortem swabs, 120 tested positive, and the combined SE and EBOV-RT-RPA yielded a sensitivity and specificity of 100% in reference to one real-time RT-PCR assay. Another widely used real-time RT-PCR was much less sensitive than expected. Results were provided very fast within 30 to 60 minutes, and the field deployment of the mobile laboratory helped improve burial management and community engagement.
Related Links:
Institut Pasteur de Dakar
Qiagen
Cepheid
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more